Research programme: vascular disruptive agents - Targa Therapeutics
Alternative Names: Granzyme B/VEGF; GrB/VEGF; VEGF/rGel; VEGF/rGel-OPLatest Information Update: 11 Jan 2018
At a glance
- Originator Peregrine Pharmaceuticals; University of Texas Southwestern Medical Center
- Developer Targa Therapeutics Corporation
- Class Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic retinopathy; Solid tumours
Most Recent Events
- 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
- 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Ophthalmic)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic)